J Jiménez-Bonilla MD , A Maldonado MD , S Morales MD , A Salud MD , M Zomeño MD , J Román MD , J Belon MD , F Moya MD
{"title":"18F-FDG-PET对血清肿瘤标志物水平升高怀疑卵巢癌复发的临床影响","authors":"J Jiménez-Bonilla MD , A Maldonado MD , S Morales MD , A Salud MD , M Zomeño MD , J Román MD , J Belon MD , F Moya MD","doi":"10.1016/S1095-0397(01)00053-X","DOIUrl":null,"url":null,"abstract":"<div><p><strong>Purpose:</strong> To retrospectively evaluate the contribution of 18F-fluorodeoxy-glucose-positron emission tomography (FDG-PET) to the diagnosis and clinical management of patients who were suspected of recurrent ovarian carcinoma, based on elevated tumor markers levels with normal or equivocal computed tomography (CT) or nuclear magnetic resonance (NMR).</p><p><strong>Procedures:</strong> 20 patients with these characteristics underwent FDG-PET. PET findings were confirmed in 14, in 7 by surgery, and in the other 7 by clinical course.</p><p><strong>Results:</strong> Recurrence was confirmed in 12 patients, all with FDG-PET positive. In other 2, recurrence was rule out and in 1, FDG-PET was negative. FDG-PET accuracy was 93% with 4 surgeries avoided and guided other 6.</p><p><strong>Conclusions:</strong> FDG-PET is an useful technique for detecting recurrent ovarian carcinoma suspected by elevated tumor markers levels and normal or equivocal results in the morphologic imaging techniques and has an important clinical impact on the management of these patients.</p></div>","PeriodicalId":80267,"journal":{"name":"Clinical positron imaging : official journal of the Institute for Clinical P.E.T","volume":"3 6","pages":"Pages 231-236"},"PeriodicalIF":0.0000,"publicationDate":"2000-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1095-0397(01)00053-X","citationCount":"29","resultStr":"{\"title\":\"Clinical Impact of 18F-FDG-PET in the Suspicion of Recurrent Ovarian Carcinoma Based on Elevated Tumor Marker Serum Levels\",\"authors\":\"J Jiménez-Bonilla MD , A Maldonado MD , S Morales MD , A Salud MD , M Zomeño MD , J Román MD , J Belon MD , F Moya MD\",\"doi\":\"10.1016/S1095-0397(01)00053-X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><strong>Purpose:</strong> To retrospectively evaluate the contribution of 18F-fluorodeoxy-glucose-positron emission tomography (FDG-PET) to the diagnosis and clinical management of patients who were suspected of recurrent ovarian carcinoma, based on elevated tumor markers levels with normal or equivocal computed tomography (CT) or nuclear magnetic resonance (NMR).</p><p><strong>Procedures:</strong> 20 patients with these characteristics underwent FDG-PET. PET findings were confirmed in 14, in 7 by surgery, and in the other 7 by clinical course.</p><p><strong>Results:</strong> Recurrence was confirmed in 12 patients, all with FDG-PET positive. In other 2, recurrence was rule out and in 1, FDG-PET was negative. FDG-PET accuracy was 93% with 4 surgeries avoided and guided other 6.</p><p><strong>Conclusions:</strong> FDG-PET is an useful technique for detecting recurrent ovarian carcinoma suspected by elevated tumor markers levels and normal or equivocal results in the morphologic imaging techniques and has an important clinical impact on the management of these patients.</p></div>\",\"PeriodicalId\":80267,\"journal\":{\"name\":\"Clinical positron imaging : official journal of the Institute for Clinical P.E.T\",\"volume\":\"3 6\",\"pages\":\"Pages 231-236\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1095-0397(01)00053-X\",\"citationCount\":\"29\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical positron imaging : official journal of the Institute for Clinical P.E.T\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S109503970100053X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical positron imaging : official journal of the Institute for Clinical P.E.T","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S109503970100053X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical Impact of 18F-FDG-PET in the Suspicion of Recurrent Ovarian Carcinoma Based on Elevated Tumor Marker Serum Levels
Purpose: To retrospectively evaluate the contribution of 18F-fluorodeoxy-glucose-positron emission tomography (FDG-PET) to the diagnosis and clinical management of patients who were suspected of recurrent ovarian carcinoma, based on elevated tumor markers levels with normal or equivocal computed tomography (CT) or nuclear magnetic resonance (NMR).
Procedures: 20 patients with these characteristics underwent FDG-PET. PET findings were confirmed in 14, in 7 by surgery, and in the other 7 by clinical course.
Results: Recurrence was confirmed in 12 patients, all with FDG-PET positive. In other 2, recurrence was rule out and in 1, FDG-PET was negative. FDG-PET accuracy was 93% with 4 surgeries avoided and guided other 6.
Conclusions: FDG-PET is an useful technique for detecting recurrent ovarian carcinoma suspected by elevated tumor markers levels and normal or equivocal results in the morphologic imaging techniques and has an important clinical impact on the management of these patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
